根据名称进行药物检索

Nifedical XL与CHF / AMI

Nifedical XL与CHF / AMI安全配伍检测的结果。

检测结果:

Nifedical XL <> CHF / AMI

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

钙通道阻滞剂(建行)可能有不同程度的消极力效果。充血性心力衰竭(瑞士法郎)，日益恶化的瑞士法郎，肺水肿发生了一些患者的治疗建行，主要是维拉帕米。一些建行也造成轻度至中度周围水肿由于本地化的血管扩张的依赖性微动脉和毛细血管，这可以混淆的影响，增加左心室功能障碍。虽然一些建行已经在治疗中使用的瑞士法郎，治疗与建行应给予谨慎地在患有严重的左心室功能障碍(例如，喷射分数<30%)或中度至严重的症状心脏衰竭以及在患有任何程度的心功能障碍，如果他们正接受一个貝塔-肾上腺素能拦截。同样，谨慎建议，在患有急性心肌梗塞和肺充血的记录X射线上入学，因为关心的失败可能严重恶化，通过管理银.

来源

Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992): s53-7
"Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.
Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994): 634-46
Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996): 216-25
Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995): 618-49
Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985): 161-3
Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998): 38-46
Prigogine T, Waterlot Y, Gottignies P, et al "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991): 563-4
Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995): 1-7
"Product Information. Norvasc (amlodipine)." Pfizer US Pharmaceuticals, New York, NY.
Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990): s85-9
Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986): 133-6
Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991): 1193-206
Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985): s139-42
Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989): 98-102
"Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.
Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994): 997-1008
Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995): 484-92
Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989): 452-60
"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc, Palo Alto, CA.
Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980): 1420-1
Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993): 261-75
"Product Information. DynaCirc (isradipine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986): 715-21
Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998): 381
"Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.
Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999): 1447-57
Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989): 70-4
"Product Information. Nimotop (nimodipine)." Bayer, West Haven, CT.